Macquarie Group’s Alpine Immune Sciences Inc ALPN Stock Holding History

Macquarie Group’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-700	Closed	-$8K	–	2415
2017 Q4	$8K	Buy	+700	New	+$7.62K	﹤0.01%	2316

Other funds holding ALPN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Macquarie Group's ALPN Position: Q1 2018 in Review

Macquarie Group sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2018, closing a stake of 700 shares — an estimated $8K sold.

Macquarie Group first reported a position in ALPN in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 28 funds tracked by Wall St. Rank hold ALPN as of Q1 2018.

Macquarie Group reported no remaining Alpine Immune Sciences Inc position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 700 Alpine Immune Sciences Inc shares in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Alpine Immune Sciences Inc in Q4 2017 and held it in 1 quarter.
Macquarie Group's Alpine Immune Sciences Inc position peaked at $8K in Q4 2017.
28 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.